Psyence Biomedical LTD. is a US-listed company in the biotechnology industry. Its financial year ends in March.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: share count (1m) is 0.24x the cover-page count (2m).
Price vs value
Under review: share count (1m) is 0.24x the cover-page count (2m). We'll show the comparison once resolved.
Psyence Biomedical LTD. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Funds7 adding, 0 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Share count rising (dilution): Diluted shares outstanding rose 1688.1% year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Psyence Biomedical LTD.'s latest figures clears our strength thresholds.
Things to watch
- Share dilution. Diluted shares rose 1688.1% in a year.
Price chart
- 1 day-3.9%
- 1 week-13.1%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-12.56
Growth
- Share count change
- +1688.1%
Cash
- Free cash flow (TTM)
- -$8.1M
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for PBM from the sources we follow. See filings →
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
No analyst estimates are published for Psyence Biomedical LTD.: too few analysts cover it.
Positioning
- Short interest
- 0.8% of tradable shares
- Days to cover
- 0.26 at average volume
- Short interest, 1 month
- −58% to October 15, 2026
- Held by institutions
- 13% of shares
- Held by insiders
- 3.0% of shares
- Employees
- 12 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial health
- Short-term assets cover short-term liabilities The company doesn't report a short-term split. Not assessable.
- Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Dividends, buybacks and capital spending
- Diluted share count
- +1688.1%
- year over year
Who owns it
Funds buying and selling- Reported value
- $1.2M
- Institutions reporting
- 9
- Shares held vs prior quarter
- ▲ 143.6%
- Positions opened / closed
- 7 / 0
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Parallel Advisors, LLC | $574,750 | 151K | 46.4% | 0.0% |
| Advisorshares Investments LLC | $373,883 | 122K | 30.2% | New |
| Morgan Stanley | $115,680 | 38K | 9.3% | New |
| Jane Street Group, LLC | $93,119 | 30K | 7.5% | New |
| Xtx Topco Ltd | $46,188 | 15K | 3.7% | New |
| Citadel Advisors LLC | $35,781 | 12K | 2.9% | New |
| Stonehage Fleming Financial Services Holdings Ltd | $272 | 0K | 0.0% | 0.0% |
| UBS Group AG | $184 | 0K | 0.0% | New |
| Caitlin John, LLC | $107 | 0K | 0.0% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Psyence Biomedical LTD.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chartFrom insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Psyence Biomedical LTD. in brief
- What does Psyence Biomedical LTD. do?
- Psyence Biomedical LTD. is a US-listed company in the biotechnology industry. Its financial year ends in March.
- What is Psyence Biomedical LTD.'s stock ticker?
- Psyence Biomedical LTD. trades under the ticker PBM on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Psyence Biomedical LTD.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Parallel Advisors, LLC, Advisorshares Investments LLC and Morgan Stanley. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Follow research on Psyence Biomedical LTD.
New research on the companies we cover arrives in the weekly email. Free, one email a week.